Search results
2 dni temu · According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Arrowhead Pharmaceuticals is $45.33, with a high forecast of $62.00 and a low forecast of $27.00.
2 dni temu · Analyst Forecast. According to 11 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $45.33, which is an increase of 121.23% from the latest price.
Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing.
11 paź 2024 · Stock Price Forecast. The 9 analysts with 12-month price forecasts for ARWR stock have an average target of 45.33, with a low estimate of 27 and a high estimate of 62. The average target predicts an increase of 145.82% from the current stock price of 18.44. Analyst Consensus: Buy.
Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn more about ARWR stock here.
5 dni temu · Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes.
Get the latest Arrowhead Pharmaceuticals Inc (ARWR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
